Bavituximab
- CAS No.
- 648904-28-3
- Chemical Name:
- Bavituximab
- Synonyms
- Tarvacin;BAVITUXIMAB;Anti-PS MAb 3G4;Research Grade Bavituximab;Bavituximab (anti-Phosphatidylserine);Research Grade Bavituximab (DGK10101)
- CBNumber:
- CB51090946
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | Q16CT95N25 |
| NCI Dictionary of Cancer Terms | bavituximab; Tarvacin |
| NCI Drug Dictionary | bavituximab |
Bavituximab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620980 | Bavituximab 97.00% | 648904-28-3 | 1mg | $542 | 2026-06-04 | Buy |
| ChemScene | CS-0620980 | Bavituximab 97.00% | 648904-28-3 | 5mg | $1354 | 2026-06-04 | Buy |
| ChemScene | CS-0620980 | Bavituximab 97.00% | 648904-28-3 | 10mg | $2167 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1944794 | Bavituximab Antibody >95% | 648904-28-3 | 1mg | $460 | 2026-05-06 | Buy |
| Biorbyt Ltd | orb1944794 | Bavituximab Antibody >95% | 648904-28-3 | 5mg | $1030 | 2026-05-06 | Buy |
Bavituximab Chemical Properties, Uses, Production
Uses
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].
in vivo
Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2].
| Animal Model: | Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] |
| Dosage: | 100 μg/mouse (Bavituximab/β2GP1) |
| Administration: | Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) |
| Result: | Traced phosphatidylserine exposure in vivo in mice with tumors. |
References
[1] Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. DOI:10.1016/j.lungcan.2014.08.010
[2] Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. DOI:10.1245/s10434-016-5107-5
Bavituximab Preparation Products And Raw materials
Raw materials
Preparation Products
Bavituximab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2110 | 70 |
| Beijing HuaMeiHuLiBiological Chemical | 010-56205725 | waley188@sohu.com | China | 12323 | 58 |
| NCE Biomedical Co.,Ltd. | 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 | China | 1490 | 55 | |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
View Latest Price from Bavituximab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-21 | Bavituximab
648904-28-3
|
$413.00-1650.00 | > 95% | 10g | TargetMol Chemicals Inc. |
-
- Bavituximab
648904-28-3
- $413.00-1650.00
- > 95%
- TargetMol Chemicals Inc.
